Sitravatinib plus nivolumab does not improve survival in NSCLC after immunotherapy and chemotherapy
The SAPPHIRE trial failed to meet its primary endpoint compared with chemotherapy
The SAPPHIRE trial failed to meet its primary endpoint compared with chemotherapy
Results from the TRACERx study suggest a potential role of CHIP as a prognostic biomarker, but further research is needed
Extended analyses from two regulatory phase III trials show that the benefits of anti-PD-1-based therapy persist long term, even in patients with brain metastases
Data from two studies improve knowledge of how to treat patients with a disease harbouring this molecular alteration and how to monitor response to treatment
Final OS analysis of the phase III CONTACT-01 trial reports negative results for immunotherapy versus docetaxel in patients progressing on checkpoint inhibitors plus chemotherapy
Additional exploratory analyses of the phase III CheckMate 816 trial reveal that event-free survival at 3 years is not influenced by surgical parameters and suggest that tumour inflammation may be a useful predictive biomarker
Updated results from the CHRYSALIS trial also suggest a number of biomarkers predictive of sustained clinical benefit with the EGFR–MET bispecific antibody
Patients consider side-effects of the KRAS G12C inhibitor to be more tolerable and to have less interference on their lives than those due to docetaxel
The key to overcoming barriers to effective prevention and treatment in resource-restricted settings involves cooperation between multiple organisations, including medical societies, patient groups, pharmaceutical companies and regulatory agencies
ESMO is contributing to making European Union legislation stricter on exposure limits for air pollution and asbestos to prevent new lung cancer cases
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.